Paul Enck

Prof. Paul Enck

Director of Research, Dept. of Internal Medicine VI: Psychosomatic Medicine and Psychotherapy, Osianderstr. 5, 72076 Tuebingen, Germany
orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2016 in Nature Reviews Disease Primers
Verified
Journal Article
Closed access
PDF file
PEPaul Enck
Paul Enck
QAQasim Aziz
Qasim Aziz
GBGiovanni Barbara
Giovanni Barbara
AFAdam D. Farmer
Adam D. Farmer
SFShin Fukudo
Shin Fukudo
PSProfessor Spiller
Professor Spiller

8 April 2017 in European Journal of Nutrition
Verified
Journal Article
Closed access
PDF file
NTNarges Tajik
Narges Tajik
MTMahboubeh Tajik
Mahboubeh Tajik
IMIsabelle Mack
Isabelle Mack
PEPaul Enck
Paul Enck

1 March 2013 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PEPaul Enck
Paul Enck
UBUlrike Bingel
Ulrike Bingel
MSManfred Schedlowski
Manfred Schedlowski
WRWinfried Rief
Winfried Rief

12 June 2018 in Psychotherapy and Psychosomatics
Verified
Journal Article
Open access
PDF file
AEAndrea W.M. Evers
Andrea W.M. Evers
LCLuana Colloca
Luana Colloca
CBCharlotte Blease
Charlotte Blease
MAMarco Annoni
Marco Annoni
LALauren Y. Atlas
Lauren Y. Atlas
JKJohn M. Kelley
John M. Kelley
Background: Placebo and nocebo effects occur in clinical or laboratory medical contexts after administration of an inert treatment or as part of active treatments and are due to psychobiological mechanisms such as expectancies of the patient. Placebo and nocebo studies have evolved from predominantly methodological research into a far-reaching interdisciplinary field that is unravelling the neurobiological, behavioural and clinical underpinnings of these phenomena in a broad variety of medical conditions. As a consequence, there is an increasing demand from health professionals to develop expert recommendations about evidence-based and ethical use of placebo and nocebo effects for clinical practice. Methods: A survey and interdisciplinary expert meeting by invitation was organized as part of the 1st Society for Interdisciplinary Placebo Studies (SIPS) conference in 2017. Twenty-nine internationally recognized placebo researchers participated. Results: There was consensus that maximizing placebo effects and minimizing nocebo effects should lead to better treatment outcomes with fewer side effects. Experts particularly agreed on the importance of informing patients about placebo and nocebo effects and training health professionals in patient-clinician communication to maximize placebo and minimize nocebo effects. Conclusions: The current paper forms a first step towards developing evidence-based and ethical recommendations about the implications of placebo and nocebo research for medical practice, based on the current state of evidence and the consensus of experts. Future research might focus on how to implement these recommendations, including how to optimize conditions for educating patients about placebo and nocebo effects and providing training for the implementation in clinical practice.

1 July 2008 in Neuron
Verified
Journal Article
Closed access
PEPaul Enck
Paul Enck
FBFabrizio Benedetti
Fabrizio Benedetti
MSManfred Schedlowski
Manfred Schedlowski

30 October 2016 in Journal of Neurogastroenterology and Motility
Verified
Journal Article
Open access
PDF file
HWHuiying Wang
Huiying Wang
ILIn-Seon Lee
In-Seon Lee
CBChristoph Braun
Christoph Braun
PEPaul Enck
Paul Enck
Huiying Wang, In-Seon Lee, Christoph Braun, Paul Enck. J Neurogastroenterol Motil 1999;0:. http://dx.doi.org/10.5056/jnm16018